GET DAILY SIGNALSAmneal Pharmaceuticals (AMRX): Analyst Targets Suggest +19% Upside Potential
Key Takeaways
- The central $24 target is the arithmetic mean of seven verified analyst price targets reviewed, which average roughly $24.3 and round to $24.
- Individual targets range from a low of $20 (Barclays) to a high of $28 (UBS), against a latest price near $20.14, implying about 19% upside.
- All recent ratings are constructive (Buy, Overweight, or Outperform), with no current Hold or Sell ratings among the firms tracked.
- The strongest supports are the biosimilars platform, the Kashiv BioSciences acquisition, the Crexont and lanreotide franchises, and a second-quarter EPS beat.
- The biggest risks are execution in the generic retail (GRx) segment, softer distribution guidance, elevated leverage, and a rich trailing valuation.
- Readers can review additional Major News, Today's Price Move, the Forecast, and Earnings pages for updated detail on the ticker.
Analyst Price Targets and Consensus View
AMRX is the ticker for Amneal Pharmaceuticals, Inc., a Nasdaq-listed developer and manufacturer of generic and specialty medicines. The $24 central target is calculated from seven current analyst price targets: UBS at $28, Oppenheimer at $27, Leerink Partners at $25, JPMorgan at $25, Goldman Sachs at $24, Piper Sandler at $21, and Barclays at $20. The arithmetic mean is about $24.3, rounded to $24, with a $20–$28 range.
The ratings cluster is decisively bullish. UBS raised its target to $28 from $25, citing second-quarter results and upcoming biosimilar and generic launches. Oppenheimer, which initiated at $27, describes Amneal at a "fundamental inflection." Leerink and JPMorgan point to the Affordable Medicines portfolio, biosimilars, and the Crexont and lanreotide franchises. Goldman Sachs lifted its target to $24, while Barclays, the most conservative at $20, flags the pending gLanreotide approval as a potential catalyst. The range is wide, which reflects genuine disagreement about how quickly new launches convert into durable earnings power. I also checked the latest consensus using Tickeron’s AI Daily Buy/Sell Signals to see how sentiment aligns with these targets.
Current Market Position and Path Toward the Target
With the stock near $20.14, reaching $24 requires roughly a 19% advance—a substantial move from a name already up sharply, with a 52-week range of about $11.30 to $21.68. The company generated roughly $3.2 billion in trailing revenue and a market capitalization near $7 billion, with a forward P/E near 17 but a trailing P/E near 50, reflecting expectations for significant earnings growth.
The path toward the target depends on execution: converting biosimilars and specialty launches into revenue and EBITDA growth while stabilizing generic retail pricing. The stock recently pulled back after its third-quarter report despite solid fundamentals, underscoring how much of the story is already priced into a sharp year-to-date rally.
What Could Support a Move Toward the Target
- The biosimilars platform, reinforced by the Kashiv acquisition, targets $1 billion to $1.3 billion of revenue by 2030.
- Crexont in Parkinson's disease, the lanreotide franchise, and Women's Health offer differentiated, higher-margin growth.
- Amneal beat estimates in the second quarter, reporting EPS of $0.30 versus a roughly $0.23 consensus, and reaffirmed fiscal 2026 revenue guidance of $3.05 billion to $3.15 billion.
- Rising analyst targets reflect improving earnings visibility, with management's 2030 revenue goal of $4.25 billion providing a longer-term framework.
What Could Prevent the Target From Being Reached
- Softer generic retail (GRx) performance and distribution segment guidance that sat slightly below Street expectations.
- Elevated leverage, with net leverage previously reported around 3.5x and a high debt-to-equity ratio, constraining flexibility.
- A stretched trailing valuation that leaves little room for disappointment if execution or pricing falters.
- Execution and launch risk in biosimilars, a competitive area where uptake and reimbursement can be unpredictable.
Technical Levels and Market Structure
The stock is trading within sight of its 52-week high of $21.68, which now acts as a nearby resistance level; a decisive move above it would represent a fresh multi-year high. The recent post-earnings pullback found footing near $19.45, which serves as near-term support. Below that, the broader uptrend remains intact well above the $11.30 52-week low, but the gap between price and the $24 target means the advance would likely require fundamental confirmation rather than momentum alone.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms do not always state the period explicitly. Investors should watch quarterly earnings and guidance, the progression of the biosimilars and lanreotide launches, the pending gLanreotide approval decision, and any revisions to fiscal 2026 EBITDA and EPS guidance. Changes in generic drug pricing, interest rates, and sector sentiment toward healthcare names are also relevant. From what I see, monitoring these elements closely helps clarify whether the targets remain realistic.
Exploring AI Tools for Stock Analysis
I often turn to Tickeron’s AI Daily Buy/Sell Signals when evaluating names like this one. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use the signals to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. For those following AMRX and similar names, the tool offers a data-driven way to track evolving momentum alongside traditional research.
Final Assessment
The question of whether Amneal Pharmaceuticals can reach $24 centers on whether it can deliver on a growth narrative that is only partly reflected in today's price. The $24 target is the average of seven current analyst targets spanning $20 to $28, implying a substantial but not extreme 19% move. Bullish analysts see biosimilars, Crexont, and lanreotide driving a fundamental inflection, while the wide target range reflects real uncertainty about generic retail execution, leverage, and a demanding valuation. The near-term catalysts—earnings, biosimilar launches, and the gLanreotide decision—will determine whether the stock can build on its sharp rally. As with any equity, the target is a research reference point, not a guarantee, and outcomes will depend on execution and market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AMRX in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 26, 2026
AMRX broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 52 similar instances where the stock broke above the upper band. In 37 of the 52 cases the stock fell afterwards. This puts the odds of success at 71%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for AMRX moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 32 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMRX as a result. In 56 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for AMRX turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 28 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 58 cases where AMRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
Following a +1.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRX advanced for three days, in 243 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. AMRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AMRX's P/B Ratio (212.412) is very high in comparison to the industry average of (7.254). P/E Ratio (40.280) is within average values for comparable stocks, (0.575). Projected Growth (PEG Ratio) (1.947) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (1.899) is also within normal values, averaging (181.047).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products
Industry PharmaceuticalsGeneric
Advertisement